Therapeutics targeting misfolding protein diseases

Amyl Therapeutics is pioneering a novel approach to treating amyloid-mediated diseases through its development of Pan-Amyloid Immunotherapy (PAI). This innovative therapy targets the conserved conformation found in all amyloid aggregates, allowing it to address a wide range of conditions associated with protein misfolding and aggregation, particularly neurodegenerative diseases. PAI is designed to clear amyloid fibrils in the later stages of disease progression while also inhibiting the formation of early-stage aggregates and dissolving existing early aggregates, thus offering both therapeutic and preventative applications.

The company is advancing a robust pipeline focused on both systemic and neurodegenerative amyloid-mediated diseases, with its most developed candidate targeting light chain (AL) amyloidosis. Amyl Therapeutics has demonstrated proof of concept for addressing neurodegenerative diseases linked to misfolded proteins such as amyloid beta, Tau, and Alpha-synuclein. Additionally, the company is leveraging novel, AI-supported technologies to enhance the efficacy, efficiency, and safety of its therapeutic molecules, positioning itself at the forefront of innovation in the treatment of amyloid-related conditions.

Belgium

Amyl therapeutics is a preclinical-stage biotechnology company pioneering a breakthrough approach to treating rare and severe peripheral protein misfolding diseases. By developing novel therapies that recognize and target multiple misfolded proteins, we aim to make a transformative impact on the lives of patients affected by systemic amyloidosis.

Our approach is shaped by an experienced team with deep drug development experience, and productive collaborations with world-class advisors and partners.

Amyl Therapeutics

Company Details